These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2861 related articles for article (PubMed ID: 24002080)

  • 1. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
    Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH
    J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA; Pampaloni MH; Nakakura E; VanBrocklin H; Slater J; Jivan S; Aparici CM; Yee J; Bergsland E
    Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of supra-aortic arterial wall inflammation in patients with arteritis using high resolution dynamic contrast-enhanced magnetic resonance imaging: initial results in correlation to [18F]-FDG PET/CT.
    Cyran CC; Sourbron S; Bochmann K; Habs M; Pfefferkorn T; Rominger A; Raya JG; Reiser MF; Dichgans M; Nikolaou K; Hacker M; Saam T
    Invest Radiol; 2011 Sep; 46(9):594-9. PubMed ID: 21577125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
    Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
    Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 144.